HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 97.49% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Wedbush reiterated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. BMO Capital Markets cut their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $21.14.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $11.14 on Friday. Y-mAbs Therapeutics has a 12-month low of $5.04 and a 12-month high of $20.90. The business’s fifty day moving average price is $13.98 and its 200 day moving average price is $13.08. The stock has a market capitalization of $498.96 million, a PE ratio of -20.63 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the business posted ($0.18) earnings per share. As a group, research analysts anticipate that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. This trade represents a 14.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the sale, the insider now owns 97,681 shares in the company, valued at approximately $1,315,763.07. This trade represents a 39.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter worth $44,000. Ameritas Investment Partners Inc. increased its stake in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after purchasing an additional 1,056 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth about $133,000. Finally, SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics during the third quarter valued at about $178,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.